Matthew Dominic Galbraith
Title | Asst Professor-Research |
---|
Institution | University of Colorado Denver - Anschutz Medical Campus |
---|
Department | SOM-PHARM General Operations |
---|
Phone | 303/724-3661 |
---|
ORCID
| 0000-0003-0485-3927 |
---|
|
|
|
Overview Research U24AG092191 (ESPINOSA, JOAQUIN M.)Sep 30, 2024 - Aug 31, 2029 NIH The INCLUDE Project Down Syndrome Biorepository (DS-Biorepository) Role: Co-Principal Investigator |
| R24OD035579 (GALBRAITH, MATTHEW D)Sep 19, 2023 - Aug 31, 2027 NIH Trisomy 21 Model Atlas Role: Principal Investigator |
Bibliographic
-
Cozzolino K, Sanford L, Hunter S, Molison K, Erickson B, Jones T, Courvan MCS, Ajit D, Galbraith MD, Espinosa JM, Bentley DL, Allen MA, Dowell RD, Taatjes DJ. Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome. bioRxiv. 2024 May 28. PMID: 37461585.
-
Wolin AR, Vincent MY, Hotz T, Purdy SC, Rosenbaum SR, Hughes CJ, Hsu JY, Oliphant MUJ, Armstrong B, Wessells V, Varella-Garcia M, Galbraith MD, Pierce A, Wang D, Venkataraman S, Danis E, Veo B, Serkova N, Espinosa JM, Gustafson DL, Vibhakar R, Ford HL. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression. Neuro Oncol. 2023 12 08; 25(12):2287-2301. PMID: 37486991.
-
D'Alessandro A, Nouraie SM, Zhang Y, Cendali F, Gamboni F, Reisz JA, Zhang X, Bartsch KW, Galbraith MD, Espinosa JM, Gordeuk VR, Gladwin MT. Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment. Haematologica. 2023 12 01; 108(12):3418-3432. PMID: 37439373.
-
Linder SJ, Bernasocchi T, Mart?nez-Pastor B, Sullivan KD, Galbraith MD, Lewis CA, Ferrer CM, Boon R, Silveira GG, Cho HM, Vidoudez C, Shroff S, Oliveira-Costa JP, Ross KN, Massri R, Matoba Y, Kim E, Rueda BR, Stott SL, Gottlieb E, Espinosa JM, Mostoslavsky R. Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cells. Nat Metab. 2023 Dec; 5(12):2131-2147. PMID: 37957387.
-
Ludwig MP, Galbraith MD, Eduthan NP, Hill AA, Clay MR, Tellez CM, Wilky BA, Elias A, Espinosa JM, Sullivan KD. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway. Cancer Res. 2023 08 01; 83(15):2543-2556. PMID: 37205634.
-
Galbraith MD, Rachubinski AL, Smith KP, Araya P, Waugh KA, Enriquez-Estrada B, Worek K, Granrath RE, Kinning KT, Paul Eduthan N, Ludwig MP, Hsieh EWY, Sullivan KD, Espinosa JM. Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition. Sci Adv. 2023 06 28; 9(26):eadg6218. PMID: 37379383.
-
Waugh KA, Minter R, Baxter J, Chi C, Galbraith MD, Tuttle KD, Eduthan NP, Kinning KT, Andrysik Z, Araya P, Dougherty H, Dunn LN, Ludwig M, Schade KA, Tracy D, Smith KP, Granrath RE, Busquet N, Khanal S, Anderson RD, Cox LL, Estrada BE, Rachubinski AL, Lyford HR, Britton EC, Fantauzzo KA, Orlicky DJ, Matsuda JL, Song K, Cox TC, Sullivan KD, Espinosa JM. Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. Nat Genet. 2023 06; 55(6):1034-1047. PMID: 37277650.
-
Hay A, Nemkov T, Gamboni F, Dzieciatkowska M, Key A, Galbraith M, Bartsch K, Sun K, Xia Y, Stone M, Busch MP, Norris PJ, Zimring JC, D'Alessandro A. Sphingosine 1-phosphate has a negative effect on RBC storage quality. Blood Adv. 2023 04 25; 7(8):1379-1393. PMID: 36469038.
-
D'Alessandro A, Nouraie SM, Zhang Y, Cendali F, Gamboni F, Reisz JA, Zhang X, Bartsch KW, Galbraith MD, Espinosa JM, Gordeuk VR, Gladwin MT. Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients, as a function of therapeutic transfusion and hydroxyurea treatment. bioRxiv. 2023 Apr 06. PMID: 37066337.
-
D'Alessandro A, Nouraie SM, Zhang Y, Cendali F, Gamboni F, Reisz JA, Zhang X, Bartsch KW, Galbraith MD, Gordeuk VR, Gladwin MT. In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction. Am J Hematol. 2023 07; 98(7):1017-1028. PMID: 36971592.
-
Szwarc MM, Guarnieri AL, Joshi M, Duc HN, Laird MC, Pandey A, Khanal S, Dohm E, Bui AK, Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. FAM193A is a positive regulator of p53 activity. Cell Rep. 2023 03 28; 42(3):112230. PMID: 36897777.
-
D'Alessandro A, Nouraie SM, Zhang Y, Cendali F, Gamboni F, Reisz JA, Zhang X, Bartsch KW, Galbraith MD, Gordeuk VR, Gladwin MT. In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction. bioRxiv. 2023 Feb 14. PMID: 36824724.
-
Tatavosian R, Donovan MG, Galbraith MD, Duc HN, Szwarc MM, Joshi MU, Frieman A, Bilousova G, Cao Y, Smith KP, Song K, Rachubinski AL, Andrysik Z, Espinosa JM. Cell differentiation modifies the p53 transcriptional program through a combination of gene silencing and constitutive transactivation. Cell Death Differ. 2023 04; 30(4):952-965. PMID: 36681780.
-
Donovan MG, Galbraith MD, Espinosa JM. Multi-omics investigation reveals functional specialization of transcriptional cyclin dependent kinases in cancer biology. Sci Rep. 2022 12 28; 12(1):22505. PMID: 36577800.
-
Araya P, Kinning KT, Coughlan C, Smith KP, Granrath RE, Enriquez-Estrada BA, Worek K, Sullivan KD, Rachubinski AL, Wolter-Warmerdam K, Hickey F, Galbraith MD, Potter H, Espinosa JM. IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome. Cell Rep. 2022 12 27; 41(13):111883. PMID: 36577365.
-
Menard-Katcher C, Liu C, Galbraith MD, Benson T, Burger C, Dobias D, Larsen L, O'Brien C, Spencer LA, Furuta GT, Masterson JC. Fibrostenotic eosinophilic esophagitis phenotype is defined by a proliferative gene signature. Allergy. 2023 02; 78(2):579-583. PMID: 36273270.
-
Galbraith MD, Kinning KT, Sullivan KD, Araya P, Smith KP, Granrath RE, Shaw JR, Baxter R, Jordan KR, Russell S, Dzieciatkowska M, Reisz JA, Gamboni F, Cendali F, Ghosh T, Guo K, Wilson CC, Santiago ML, Monte AA, Bennett TD, Hansen KC, Hsieh EWY, D'Alessandro A, Espinosa JM. Specialized interferon action in COVID-19. Proc Natl Acad Sci U S A. 2022 03 15; 119(11). PMID: 35217532.
-
Sullivan KD, Galbraith MD, Kinning KT, Bartsch KW, Levinsky NC, Araya P, Smith KP, Granrath RE, Shaw JR, Baxter RM, Jordan KR, Russell SA, Dzieciatkowska ME, Reisz JA, Gamboni F, Cendali FI, Ghosh T, Monte AA, Bennett TD, Miller MG, Hsieh EW, D'Alessandro A, Hansen KC, Espinosa JM. The COVIDome Explorer researcher portal. Cell Rep. 2021 08 17; 36(7):109527. PMID: 34348131.
-
Liggett LA, Galbraith MD, Smith KP, Sullivan KD, Granrath RE, Enriquez-Estrada B, Kinning KT, Shaw JR, Rachubinski AL, Espinosa JM, DeGregori J. Precocious clonal hematopoiesis in Down syndrome is accompanied by immune dysregulation. Blood Adv. 2021 04 13; 5(7):1791-1796. PMID: 33787858.
-
Galbraith MD, Kinning KT, Sullivan KD, Baxter R, Araya P, Jordan KR, Russell S, Smith KP, Granrath RE, Shaw JR, Dzieciatkowska M, Ghosh T, Monte AA, D'Alessandro A, Hansen KC, Benett TD, Hsieh EW, Espinosa JM. Seroconversion stages COVID19 into distinct pathophysiological states. Elife. 2021 03 16; 10. PMID: 33724185.
-
Sullivan KD, Galbraith MD, Kinning KT, Bartsch K, Levinsky N, Araya P, Smith KP, Granrath RE, Shaw JR, Baxter R, Jordan KR, Russell S, Dzieciatkowska M, Reisz JA, Gamboni F, Cendali F, Ghosh T, Monte AA, Bennett TD, Miller MG, Hsieh EWY, D'Alessandro A, Hansen KC, Espinosa JM. The COVIDome Explorer Researcher Portal. medRxiv. 2021 Mar 08. PMID: 33758879.
-
Andrysik Z, Bender H, Galbraith MD, Espinosa JM. Multi-omics analysis reveals contextual tumor suppressive and oncogenic gene modules within the acute hypoxic response. Nat Commun. 2021 03 02; 12(1):1375. PMID: 33654095.
-
Galbraith MD, Andrysik Z, Sullivan KD, Espinosa JM. Global Analyses to Identify Direct Transcriptional Targets of p53. Methods Mol Biol. 2021; 2267:19-56. PMID: 33786783.
-
Galbraith MD, Kinning KT, Sullivan KD, Baxter R, Araya P, Jordan KR, Russell S, Smith KP, Granrath RE, Shaw J, Dzieciatkowska M, Ghosh T, Monte AA, D'Alessandro A, Hansen KC, Bennett TD, Hsieh EWY, Espinosa JM. Seroconversion stages COVID19 into distinct pathophysiological states. medRxiv. 2020 Dec 07. PMID: 33330890.
-
Zhou H, Blevins MA, Hsu JY, Kong D, Galbraith MD, Goodspeed A, Culp-Hill R, Oliphant MUJ, Ramirez D, Zhang L, Trinidad-Pineiro J, Mathews Griner L, King R, Barnaeva E, Hu X, Southall NT, Ferrer M, Gustafson DL, Regan DP, D'Alessandro A, Costello JC, Patnaik S, Marugan J, Zhao R, Ford HL. Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis. Cancer Res. 2020 06 15; 80(12):2689-2702. PMID: 32341035.
-
Rizzotto D, Zaccara S, Rossi A, Galbraith MD, Andrysik Z, Pandey A, Sullivan KD, Quattrone A, Espinosa JM, Dassi E, Inga A. Nutlin-Induced Apoptosis Is Specified by a Translation Program Regulated by PCBP2 and DHX30. Cell Rep. 2020 03 31; 30(13):4355-4369.e6. PMID: 32234473.
-
Waugh KA, Araya P, Pandey A, Jordan KR, Smith KP, Granrath RE, Khanal S, Butcher ET, Estrada BE, Rachubinski AL, McWilliams JA, Minter R, Dimasi T, Colvin KL, Baturin D, Pham AT, Galbraith MD, Bartsch KW, Yeager ME, Porter CC, Sullivan KD, Hsieh EW, Espinosa JM. Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome. Cell Rep. 2019 11 12; 29(7):1893-1908.e4. PMID: 31722205.
-
Steinparzer I, Sedlyarov V, Rubin JD, Eislmayr K, Galbraith MD, Levandowski CB, Vcelkova T, Sneezum L, Wascher F, Amman F, Kleinova R, Bender H, Andrysik Z, Espinosa JM, Superti-Furga G, Dowell RD, Taatjes DJ, Kovarik P. Transcriptional Responses to IFN-? Require Mediator Kinase-Dependent Pause Release and Mechanistically Distinct CDK8 and CDK19 Functions. Mol Cell. 2019 11 07; 76(3):485-499.e8. PMID: 31495563.
-
Oliphant MUJ, Vincent MY, Galbraith MD, Pandey A, Zaberezhnyy V, Rudra P, Johnson KR, Costello JC, Ghosh D, DeGregori J, Espinosa JM, Ford HL. SIX2 Mediates Late-Stage Metastasis via Direct Regulation of SOX2 and Induction of a Cancer Stem Cell Program. Cancer Res. 2019 02 15; 79(4):720-734. PMID: 30606720.
-
Galbraith MD, Bender H, Espinosa JM. Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription. 2019 04; 10(2):118-136. PMID: 30409083.
-
Abraham CG, Ludwig MP, Andrysik Z, Pandey A, Joshi M, Galbraith MD, Sullivan KD, Espinosa JM. ?Np63a Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep. 2018 09 18; 24(12):3224-3236. PMID: 30232004.
-
Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. Mechanisms of transcriptional regulation by p53. Cell Death Differ. 2018 01; 25(1):133-143. PMID: 29125602.
-
Galbraith MD, Andrysik Z, Pandey A, Hoh M, Bonner EA, Hill AA, Sullivan KD, Espinosa JM. CDK8 Kinase Activity Promotes Glycolysis. Cell Rep. 2017 Nov 07; 21(6):1495-1506. PMID: 29117556.
-
Andrysik Z, Galbraith MD, Guarnieri AL, Zaccara S, Sullivan KD, Pandey A, MacBeth M, Inga A, Espinosa JM. Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity. Genome Res. 2017 10; 27(10):1645-1657. PMID: 28904012.
-
Audetat KA, Galbraith MD, Odell AT, Lee T, Pandey A, Espinosa JM, Dowell RD, Taatjes DJ. A Kinase-Independent Role for Cyclin-Dependent Kinase 19 in p53 Response. Mol Cell Biol. 2017 07 01; 37(13). PMID: 28416637.
-
Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, Smith KP, Liggett LA, Gomez EB, Galbraith MD, DeGregori J, Espinosa JM. Trisomy 21 consistently activates the interferon response. Elife. 2016 07 29; 5. PMID: 27472900.
-
Perez-Perri JI, Dengler VL, Audetat KA, Pandey A, Bonner EA, Urh M, Mendez J, Daniels DL, Wappner P, Galbraith MD, Espinosa JM. The TIP60 Complex Is a Conserved Coactivator of HIF1A. Cell Rep. 2016 06 28; 16(1):37-47. PMID: 27320910.
-
Nichol JN, Galbraith MD, Kleinman CL, Espinosa JM, Miller WH. NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia. Cell Rep. 2016 Mar 29; 14(12):2938-49. PMID: 26997274.
-
Allen MA, Andrysik Z, Dengler VL, Mellert HS, Guarnieri A, Freeman JA, Sullivan KD, Galbraith MD, Luo X, Kraus WL, Dowell RD, Espinosa JM. Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. Elife. 2014 May 27; 3:e02200. PMID: 24867637.
-
Dengler VL, Galbraith M, Espinosa JM. Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol. 2014 Jan-Feb; 49(1):1-15. PMID: 24099156.
-
Galbraith MD, Saxton J, Li L, Shelton SJ, Zhang H, Espinosa JM, Shaw PE. ERK phosphorylation of MED14 in promoter complexes during mitogen-induced gene activation by Elk-1. Nucleic Acids Res. 2013 Dec; 41(22):10241-53. PMID: 24049075.
-
Galbraith MD, Allen MA, Bensard CL, Wang X, Schwinn MK, Qin B, Long HW, Daniels DL, Hahn WC, Dowell RD, Espinosa JM. HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell. 2013 Jun 06; 153(6):1327-39. PMID: 23746844.
-
Henry RE, Andrysik Z, Par?s R, Galbraith MD, Espinosa JM. A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX. EMBO J. 2012 Mar 07; 31(5):1266-78. PMID: 22246181.
-
Galbraith MD, Espinosa JM. Lessons on transcriptional control from the serum response network. Curr Opin Genet Dev. 2011 Apr; 21(2):160-6. PMID: 21316215.
-
Galbraith MD, Donner AJ, Espinosa JM. CDK8: a positive regulator of transcription. Transcription. 2010 Jul-Aug; 1(1):4-12. PMID: 21327159.
-
Zhang HM, Li L, Papadopoulou N, Hodgson G, Evans E, Galbraith M, Dear M, Vougier S, Saxton J, Shaw PE. Mitogen-induced recruitment of ERK and MSK to SRE promoter complexes by ternary complex factor Elk-1. Nucleic Acids Res. 2008 May; 36(8):2594-607. PMID: 18334532.
-
Galbraith MD, Giddens SR, Mahanty HK, Clark B. Role of glutamine synthetase in phenazine antibiotic production by Pantoea agglomerans Eh1087. Can J Microbiol. 2004 Oct; 50(10):877-81. PMID: 15644904.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2004 | 1 | 2008 | 1 | 2010 | 1 | 2011 | 1 | 2012 | 1 | 2013 | 3 | 2014 | 1 | 2016 | 3 | 2017 | 4 | 2018 | 2 | 2019 | 3 | 2020 | 3 | 2021 | 6 | 2022 | 4 | 2023 | 12 | 2024 | 1 |
To return to the timeline, click here.
|
Galbraith's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|